Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-26T06:18:28.708Z Has data issue: false hasContentIssue false

IN VITRO TESTS FOR ASSESSING HEPARIN-INDUCED THROMBOCYTOPENIA IN PATIENTS AFTER ELECTIVE HIP REPLACEMENT

A Medico-economical Evaluation

Published online by Cambridge University Press:  19 December 2002

Frédéric Sobas
Affiliation:
Edouard Herriot University Hospital
Cyrille Colin
Affiliation:
Hospices Civils de Lyon
Patrick Ffrench
Affiliation:
Louis Pradel University Hospital
Marie Christine Trzeciak
Affiliation:
Edouard Herriot University Hospital
Marc Dechavanne
Affiliation:
Edouard Herriot University Hospital
Claude Négrier
Affiliation:
Edouard Herriot University Hospital

Abstract

Objectives: Considering the previously published incidences of heparin-induced thrombocytopenia (HIT) in patients receiving a thromboprophylactic therapy, the role of the hemostasis laboratory is essential in making a clinical decision. The purpose of this project was to compare the strategies of diagnosis and associated care of patients with suspected HIT after elective hip replacement using platelet aggregation assay, carbon 14-serotonin release, and “doing nothing.”

Methods: The authors used an incremental cost-effectiveness analysis based on data extracted from the literature. The effectiveness of the strategies was represented by the number of deep venous thromboses prevented. Cost data were collected from the observation of biological and medical practice at Edouard Herriot University Hospital, Lyon, France, in 1999.

Results: In comparison with the strategies of doing nothing using no biological test for diagnosis, and clinical care of HIT-suspected patients, the strategy using platelet aggregation test was more expensive and less effective. With respect to the strategy using carbon 14-serotonin release assay, the incremental cost-effectiveness ratio, expressed as U.S. dollars per deep venous thrombosis prevented, reached $200,000, with a marginal effectiveness of eight deep venous thromboses prevented for 10,000 HIT-suspected patients.

Conclusion: This study suggests that clinical hemostasis laboratories might consider replacing the platelet aggregation test with the carbon 14-serotonin release assay or should use another functional assay such as the flow cytometric assay for the diagnosis and care of patients with suspected HIT.

Type
GENERAL ESSAYS
Copyright
© 2002 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)